Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    nct01461837
Show Display Options
Rank Status Study
1 Recruiting Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: CD34 selected T-cell depleted allogeneic SCT
2 Not yet recruiting Myeloablative Conditioning and Haplo AlloSCT for Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Defibrotide

Indicates status has not been verified in more than two years